South African guideline for the management of chronic hepatitis B: 2013

South African Medical Journal

Volumn 103, Issue 5, 2013, Pages 335-349

  Spearman, C W N ^a   Sonderup, Mark W ^a,b   Botha, J F ^b,c   van der Merwe, S W ^d,e   Song, E ^f,g   Kassianides, C ^h,i   Newton, K A ^b,j   Hairwadzi, H N ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b South African Gastroenterology Society   (South Africa)

^c Sandton Clin   (South Africa)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g University of the Witwatersrand   (South Africa)

^h Morningside Clinic   (South Africa)

ⁱ Gastroenterology Foundation of South Africa   (South Africa)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; EMTRICITABINE; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B (E) ANTIBODY; HEPATITIS B (E) ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RITUXIMAB; TENOFOVIR; THYROTROPIN; UNCLASSIFIED DRUG; VIRUS DNA;

ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RISK; CANCER SCREENING; DOPPLER FLOWMETRY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; END STAGE LIVER DISEASE; FATIGUE; FLU LIKE SYNDROME; HEALTH CARE PERSONNEL; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOLOGICAL TOLERANCE; KIDNEY GRAFT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NEUTROPENIA; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; PROPHYLAXIS; REPEATED DRUG DOSE; SEROLOGY; SIDE EFFECT; SOUTH AFRICA; THROMBOCYTOPENIA; VACCINATION; VIRUS CARRIER; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REPLICATION; WEIGHT REDUCTION;

EID: 84877677881     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.6452     Document Type: Article

References (76)

1. Vardas E, Mathai M, Blaauw D, et al. Preimmunization epidemiology of Hepatitis B virus infection in South African children. J Med Virology 1999;58:111-115. [http://dx.doi.org/10.1002/(SICI)1096-9071(199906)58:2111::AID-JMV23.0.CO;2-B]
2. Huang K, Lin S. Nationwide vaccination: A success story in Taiwan. Vaccine 2000;18:S35-38. [http://dx.doi.org/10.1016/S0264-410X(99)00460-0]
3. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic Hepatitis B in co-infected patients. J Hepatology 2006; 44: S65-S70. [http://dx.doi.org/10.1016/j.jhep.2005.11.015]
4. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49:S45-S55. [http://dx.doi.org/10.1002/hep.22898]
5. Lok ASF, McMahon BJ. AASLD Practice Guidelines. Chronic Hepatitis B: Update 2009. Hepatology 2009;50(3):1-36.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
7. Liaw YF, Kao JH, Piratvisuth T et al. Asian-Pacific consensus statement on management of chronic Hepatitis B: A 2012 update - Asian-Pacific Association for the Study of the Liver (APASL). Hepatol Int 2012;6:531-561.
8. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B. Ann Intern Med 2009;150:104-110. [http://dx.doi.org/10.1002/hep.22946]
9. World Gastroenterology Organisation Practice Guideline: Hepatitis B. September 2008. http://worldgastroenterology.org/hepatitis-b.html (accessed 11 April 2013).
10. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97-107. [http://dx.doi.org/10.1046/j.1365-2893.2003.00487.x]
11. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of Hepatitis B: Summary of a clinical research workshop. Hepatology 2007;45(4):1056-1075. [http://dx.doi.org/10.1002/hep.21627]
12. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151(4):599-603. [http://dx.doi.org/10.1093/infdis/151.4.599]
13. Wieland SF, Chisari FV. Stealth and cunning: Hepatitis B and C viruses. J Virol 2005;79(15):9369-9380. [http://dx.doi.org/10.1128/JVI.79.15.9369-9380.2005]
14. Yim HJ, Lok AS. Natural history of chronic hepatitis B infection: What we knew in 1981 and what we know in 2005. Hepatology 2006;43(2):S173-S181. [http://dx.doi.org/10.1002/hep.20956]
15. Jacobson IM, Martin P, Schiff ER, Tobias H. A treatment algorithm for management of chronic Hepatitis virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6(12):1315-1341. [http://dx.doi.org/10.1016/j.cgh.2008.08.021]
16. Lok AS, McMahon BJ. Chronic Hepatitis B. Hepatology 2007;45(2):507-539. [http://dx.doi.org/10.1002/hep.21513]
17. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic Hepatitis B: Natural history and treatment. Semin Liver Dis 2006;26(2):130-141. [http://dx.doi.org/10.1055/s-2006-939751]
18. Keefe EB, Dieterich DT, Han SH, et al. A treatment algorithm for management of chronic Hepatitis virus infection in the United States. Clin Gastroenterol Hepatol 2004;2(2):87-106. [http://dx.doi.org/10.1016/S1542-3565(03)00312-4]
19. Colloredo MG, Leandro G, Brunetto MR, et al. Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol 1993;8:203-211.
20. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic Hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531. [http://dx.doi.org/10.1056/NEJMoa033364]
21. Chen CJ, Iloeje UH, Yang H. Long-term outcomes in Hepatitis B: The REVEAL-HBV study. Clin Liver Dis 2007;11:797-816. [http://dx.doi.org/10.1016/j.cld.2007.08.005]
22. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating Hepatitis B viral load. Gastroenterology 2006;130(3):678-686. [http://dx.doi.org/10.1053/j.gastro.2005.11.016]
23. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65-73. [http://dx.doi.org/10.1001/jama.295.1.65]
24. Keefe EB, Dieterich DT, Han SH, et al. A treatment algorithm for management of chronic Hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006;4(8):936-962. [http://dx.doi.org/10.1016/j.cgh.2006.05.016]
25. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64(1):51-68. [http://dx.doi.org/10.1128/MMBR.64.1.51-68.2000]
26. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126(7):1750-1758. [http://dx.doi.org/10.1053/j.gastro.2004.03.018]
27. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol. 2010;52(4):475-477. [http://dx.doi.org/10.1016/j.jhep.2009.12.020]
28. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013;381(9865):468-475.
29. Degertekin B, Lok AS. Indications for therapy in Hepatitis B. Hepatology 2009;49:S129-S137. [http://dx.doi.org/10.1002/hep.22931]
30. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004;11(5):427-431. [http://dx.doi.org/10.1111/j.1365-2893.2004.00504.x]
31. Loomba R, Rowley A, Wesley R, et al. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148(7):519-528.
32. Tilmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicentre experience. J Viral Hepat 2006; 13(4): 256-263. [http://dx.doi.org/10.1111/j.1365-2893.2005.00695.x]
33. Hoofnagle JH. Reactivation of Hepatitis B. Hepatology 2009;49:S156-S165. [http://dx.doi.org/10.1002/hep.22945]
34. Lok AS. Drug therapy: Tenofovir. Hepatology 2010;52(2):743-747. [http://dx.doi.org/10.1002/hep.23788]
35. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005;365(9454):123-129. [http://dx.doi.org/10.1016/S0140-6736(05)17701-0]
36. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine and the combination for HB eAg-positive chronic Hepatitis B. N Engl J Med 2005;352(26):2682-2695. [http://dx.doi.org/10.1056/NEJMoa043470]
37. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with peginterferon alpha-2b for HB eAg-positive chronic hepatitis B: HB sAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101(2):297-303. [http://dx.doi.org/10.1111/j.1572-0241.2006.00418.x]
38. Fried MW, Piratvisuth T, Lau GK, et al. HB eAg and Hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HB eAg-positive chronic Hepatitis B. Hepatology 2008;47(2):428-434. [http://dx.doi.org/10.1002/hep.22065]
39. Sonneveld MJ, Rijckborst V, Boucher C, Hansen BE, Janseen HL. Prediction of sustained response to peginterferon alfa-2b for HBeAg-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52(4):1251-1257. [http://dx.doi.org/10.1002/hep.23844]
40. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon {alpha}-2a, lamivudine and the two combined for HB eAg-negative chronic Hepatitis B. Gut 2007;56(5):699-705. [http://dx.doi.org/10.1136/gut.2005.089722]
41. Moucari R, Mackiewicz V, Lada O, et al. Early serum HB sAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HB eAg-negative patients. Hepatology 2009;49(4):1151-1157. [http://dx.doi.org/10.1002/hep.22744]
42. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139(2):491-498. [http://dx.doi.org/10.1053/j.gastro.2010.03.059]
43. Peters MG. Special populations with Hepatitis B virus infection. Hepatology 2009;49:S146-S155. [http://dx.doi.org/10.1002/hep.22965]
44. Hanbali A, Khaled Y. Incidence of Hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009;84(3):195. [http://dx.doi.org/10.1002/ajh.21343]
45. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Hematol 2007;136(5):699-712. [http://dx.doi.org/10.1111/j.1365-2141.2006.06465.x]
46. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and its prevention. Clin Gastroenterol Hepatol 2006;4(9):1076-1081. [http://dx.doi.org/10.1016/j.cgh.2006.05.027]
47. Liang R. How I treat and monitor viral Hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113(14):3147-3153. [http://dx.doi.org/10.1182/blood-2008-10-163493]
48. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendation for management. Hepatology 2007;46(1):254-265. [http://dx.doi.org/10.1002/hep.21698]
49. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic Hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6(12):1315-1341. [http://dx.doi.org/10.1016/j.cgh.2008.08.021]
50. Terrault NA, Jacobson IM. Treating chronic hepatitis B in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis 2007;27:18-24. [http://dx.doi.org/10.1055/s-2007-984696]
51. Chotiyaputta W, Lok AS. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat 2009;16(2):91-93. [http://dx.doi.org/10.1111/j.1365-2893.2008.01067.x]
52. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine therapy during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10(4):294-297. [http://dx.doi.org/10.1046/j.1365-2893.2003.00440.x]
53. ter Borg MJ. Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15(1):37-41. [http://dx.doi.org/10.1111/j.1365-2893.2007.00894.x]
54. Jonas MM, Little NR, Gardner SD. Long-term lamivudine treatment of children with chronic hepatitis B: Durability of therapeutic responses and safety. J Viral Hepat 2008;15(1):20-27. [http://dx.doi.org/10.1111/j.1365-2893.2007.00891.x]
55. Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: A consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999;29(2):163-170. [http://dx.doi.org/10.1097/00005176-199908000-00012]
56. Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon alpha-2b and ribavirin in patients with HBV/HCV co-infection. J Hepat 2008;49(5):688-694. [http://dx.doi.org/10.1016/j.jhep.2008.03.028]
57. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008;23(4):512-520. [http://dx.doi.org/10.1111/j.1440-1746.2008.05384.x]
58. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37(3):568-576. [http://dx.doi.org/10.1053/jhep.2003.50096]
59. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YMA. Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol 2007;22(9):1510-1518. [http://dx.doi.org/10.1111/j.1440-1746.2007.05062.x]
60. Hoffman CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007;7(6):402-409. [http://dx.doi.org/10.1016/S1473-3099(07)70135-4]
61. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. AIDS 2005;19(3):221-240. [http://dx.doi.org/10.1097/01.aids.0000163948.62176.e7]
62. Sulkowski MS. Viral hepatitis and HIV Co-infection. J Hepatol 2008;48(2):353-367. [http://dx.doi.org/10.1016/j.jhep.2007.11.009]
63. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006;43(3):548-555. [http://dx.doi.org/10.1002/hep.21055]
64. Chevillotte G, Durbec JP, Gerolami A, Berthezene P, Bidart JM, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: An epidemiologic study. Gastroenterology 1983;85(1):141-145.
65. Villa ERL, Barchi T, Ferretti I, et al. Susceptibity of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982;2(8310):1243-1245.
66. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunisation strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunisation Practices (ACIP) part 1: immunisation of infants, children and adolescents. MMWR Recomm Rep 2005;54(RR-16):1-31.
67. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007;14:37-44. [http://dx.doi.org/10.1111/j.1365-2893.2007.00916.x]
68. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348(9036):1212-1215. [http://dx.doi.org/10.1016/S0140-6736(96)04444-3]
69. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24:55-62. [http://dx.doi.org/10.1055/s-2004-828679]
70. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. Liver Transplant 2007;13(3):349-360. [http://dx.doi.org/10.1002/lt.20981]
71. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HB sAg (-), HB cAb(+), HB IgM(-) organ donors. Transplantation 1995;59(2):230-234. [http://dx.doi.org/10.1097/00007890-199501270-00014]
72. Dickson RC, Everhart JE, Lake JR, et al. Transmission of Hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113(5):1668-1674. [http://dx.doi.org/10.1053/gast.1997.v113.pm9352871]
73. Prieto M, Gomez MD, Berenguer M, et al. De novo Hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7(1):51-58. [http://dx.doi.org/10.1053/jlts.2001.20786]
74. Terrault N, Roche B, Samuel D. Management of the Hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transplan 2005;11(7):716-732. [http://dx.doi.org/10.1002/lt.20492]
75. Mutimer D. Review article: Hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006;23(8):1031-1041. [http://dx.doi.org/10.1111/j.1365-2036.2006.02855.x]
76. Bruix J, Sherman M. AASLD Practice Guideline: Management of Hepatocellular Carcinoma: An Update. Hepatology 2011;53(3):1020-1035. [http://dx.doi.org/10.1002/hep.24199]